Search results for "Biphenyl Compound"

showing 10 items of 62 documents

Influence of Dimerization of Apocynin on Its Effects in Experimental Colitis

2017

Apocynin has been widely used as an inhibitor of the nicotinamide adenine dinucleotide phosphate oxidase (NADPH-oxidase) system and shows promise as an anti-inflammatory drug. Diapocynin, the dimeric product generated by the oxidation of apocynin in the presence of myeloperoxidase (MPO), is supposed to be its active form. In this study, diapocynin has been chemically synthesized and its activity on several inflammatory mediators in LPS-stimulated RAW 264.7 macrophages and its anti-inflammatory effect on ulcerative colitis induced by dextran sodium sulfate (DSS) in mice analyzed. We found that diapocynin showed higher inhibitory activity than apocynin. The dimer reduced ROS production, TNF-α…

Male0301 basic medicineDimerInterleukin-1betaPharmacologyInhibitory postsynaptic potentialMice03 medical and health scienceschemistry.chemical_compoundIn vivoAnimalsHumansMice Inbred BALB COxidase testMolecular StructurebiologyInterleukin-6Tumor Necrosis Factor-alphaMacrophagesBiphenyl CompoundsNF-kappa BAcetophenonesGeneral ChemistryColitis030104 developmental biologychemistryDiapocyninBiochemistryCyclooxygenase 2MyeloperoxidaseApocyninbiology.proteinGeneral Agricultural and Biological SciencesDimerizationNicotinamide adenine dinucleotide phosphateJournal of Agricultural and Food Chemistry
researchProduct

Role of angiotensin II in arterial pressure and renal hemodynamics in rats with altered renal development: age- and sex-dependent differences

2012

Numerous studies have demonstrated that angiotensin II (ANG II) is involved in hypertension and renal changes occurring as a consequence of an adverse event during renal development. However, it was unknown whether this involvement is sex and age dependent. This study examines whether the increments in arterial pressure (AP) and in the renal sensitivity to ANG II are sex and age dependent in rats with altered renal development. It also evaluates whether the ANG II effects are accompanied by increments in AT1 receptors and oxidative stress. Experiments were performed in 3- to 4- and 10- to 11-mo-old rats treated with vehicle or an AT1 receptor antagonist (ARAnp) during the nephrogenic perio…

MaleAgingmedicine.medical_specialtyPhysiologyTetrazolesRenal functionKidneyAge and sexmedicine.disease_causeReceptor Angiotensin Type 1Rats Sprague-DawleyInternal medicinemedicineAnimalsArterial PressureRenal hemodynamicsFetal programmingAdverse effectSex CharacteristicsChemistryAngiotensin IIBiphenyl CompoundsAngiotensin IIMesenteric ArteriesRatsOxidative StressEndocrinologyBlood pressureBenzimidazolesFemaleAngiotensin II Type 1 Receptor BlockersOxidative stressAmerican Journal of Physiology-Renal Physiology
researchProduct

Measurement of substrate-induced oxygen uptake during microsomal drug oxidation using a gold micro-electrode.

1975

1. A resin-coated gold micro-electrode has been used for polarographic determination of oxygen concentration in liver microsomal suspensions from phenobarbital-pretreated rats. 2. The rate of oxygen uptake on addition of an NADPH-regenerating system and the rate after addition of various substrates of the mixed function oxidase system were measured. The rate of oxygen uptake was faster in the presence of substrate than in the presence of NADPH alone. 3. Kinetic constants (Km and V max) for biphenyl, hexobarbital, ethylmorphine, naphthalene and SKF 525-A measured by this technique compare favourably with those obtained either by measurements of NADPH oxidation, or chemical measurements of su…

MaleHealth Toxicology and MutagenesisInorganic chemistryHexobarbitalNaphthalenesToxicologyBiochemistryOxygen ConsumptionmedicineAnimalsPharmacologyPolarographyMorphine DerivativesCell-Free SystemMorphineChemistryProadifenBiphenyl CompoundsSubstrate (chemistry)General MedicineNADPH oxidationEthylmorphineRatsKineticsHexobarbitalMixed Function OxidaseMicrosomes LiverLimiting oxygen concentrationGoldOxidoreductasesMicroelectrodesOxidation-ReductionDrug metabolismNADPmedicine.drugPolarographyXenobiotica; the fate of foreign compounds in biological systems
researchProduct

Effect of soluble guanylyl cyclase activator and stimulator therapy on nitroglycerin-induced nitrate tolerance in rats

2015

Chronic nitroglycerin (GTN) anti-ischemic therapy induces side effects such as nitrate tolerance and endothelial dysfunction. Both phenomena could be based on a desensitization/oxidation of the soluble guanylyl cyclase (sGC). Therefore, the present study aims at investigating the effects of the therapy with the sGC activator BAY 60-2770 and the sGC stimulator BAY 41-8543 on side effects induced by chronic nitroglycerin treatment. Male Wistar rats were treated with nitroglycerin (100mg/kg/d for 3.5days, s.c. in ethanol) and BAY 60-2770 (0.5 or 2.5mg/kg/d) or BAY 41-8543 (1 and 5mg/kg/d) for 6days. Therapy with BAY 60-2770 but not with BAY 41-8543 improved nitroglycerin-triggered endothelial …

MaleHydrocarbons FluorinatedPhysiologyMorpholinesReceptors Cytoplasmic and NuclearVasodilationStimulationPharmacologymedicine.disease_causeBenzoatesNitric oxideNitroglycerinchemistry.chemical_compoundOrgan Culture TechniquesSoluble Guanylyl CyclasemedicineAnimalsPharmacology (medical)Rats WistarEndothelial dysfunctionAortaWhole bloodPharmacologyNitratesActivator (genetics)business.industryNitrotyrosineBiphenyl Compoundsmedicine.diseaseRatsBiphenyl compoundEnzyme ActivationOxidative StressPyrimidineschemistryGuanylate CyclaseMeeting Abstractcardiovascular systemMolecular MedicineSoluble guanylyl cyclasebusinessOxidative stressBMC Pharmacology and Toxicology
researchProduct

Circulating neprilysin hypothesis: A new opportunity for sacubitril/valsartan in patients with heart failure and preserved ejection fraction?

2021

BackgroundCirculating Neprilysin (sNEP) has emerged as a potential prognostic biomarker in heart failure (HF). In PARAGON-HF benefit of sacubitril/valsartan was only observed in patients with left ventricular ejection fraction (LVEF) ≤57%. We aimed to assess the prognostic value of sNEP in outpatients with HF and LVEF >57%, in comparison with patients with LVEF ≤57%.MethodsConsecutive HF outpatients were included from May-2006 to February-2016. The primary endpoint was the composite of all-cause death or HF hospitalization and the main secondary endpoint was the composite of cardiovascular death or HF hospitalization. For the later competing risk methods were used.ResultssNEP was measure…

MalePhysiologyCancer TreatmentCardiovascular MedicineBiochemistrySacubitrilMedical ConditionsClinical endpointMedicine and Health SciencesMultidisciplinaryEjection fractionPharmaceuticsAminobutyratesHazard ratioQRMiddle AgedPrognosisBody FluidsCardiovascular TherapyBloodValsartanOncologyCardiovascular DiseasesCardiologycardiovascular systemMedicineValsartanFemaleNeprilysinAnatomymedicine.drugcirculatory and respiratory physiologyResearch Articlemedicine.medical_specialtyScienceCardiologyDrug TherapyInternal medicinemedicineHumanscardiovascular diseasesAgedProportional Hazards ModelsHeart FailureProportional hazards modelbusiness.industryBiphenyl CompoundsBiology and Life SciencesStroke VolumeCardiovascular Disease Riskmedicine.diseaseHeart failurebusinessSacubitril ValsartanBiomarkersReceptor Antagonist TherapyEjection FractionPloS one
researchProduct

Biphenyl and fluorinated derivatives: liver enzyme-mediated mutagenicity detected in Salmonella typhimurium and Chinese hamster V79 cells.

1992

Abstract Hepatocarcinogenic polychlorinated and polybrominated biphenyls usually show negative results in in vitro mutagenicity assays. Problems in their testing result from their low water solubility and their slow rate of metabolism. We therefore investigated better soluble model compounds, namely biphenyl and its 3 possible monofiuorinated derivatives. In the direct test, these compounds proved tobe nonmutagenic in Salmonella typhimurium TA98 and TA100 (reversion to histidine prototrophy) and in Chinese hamster V79 cells (acquisition of resistance to 6-thioguanine). However, when the exposure was carried out in the presence of NADPH-fortified postmitochondrial fraction of liver homogenat…

MaleSalmonella typhimuriumendocrine systemChinese hamsterAmes testCell LineToxicologychemistry.chemical_compoundStructure-Activity RelationshipCricetulusCricetinaeAnimalsBiotransformationBiphenylbiologyChemistryMutagenicity TestsBiphenyl CompoundsRats Inbred StrainsGeneral MedicineMetabolismbiology.organism_classificationEnterobacteriaceaeIn vitroRatsBiochemistryMicrosomal epoxide hydrolaseMicrosomes LiverPolybrominated BiphenylsMutation research
researchProduct

A putative placebo analysis of the effects of LCZ696 on clinical outcomes in heart failure

2015

Aims: Although active-controlled trials with renin–angiotensin inhibitors are ethically mandated in heart failure with reduced ejection fraction, clinicians and regulators often want to know how the experimental therapy would perform compared with placebo. The angiotensin receptor-neprilysin inhibitor LCZ696 was compared with enalapril in PARADIGM-HF. We made indirect comparisons of the effects of LCZ696 with putative placebos.\ud \ud Methods and results: We used the treatment-arm of the Studies Of Left Ventricular Dysfunction (SOLVD-T) as the reference trial for comparison of an ACE inhibitor to placebo and the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidit…

MaleTetrazolesAngiotensin-Converting Enzyme InhibitorsEnalaprilEnalapril/therapeutic useMedicineNatriuretic peptidesAngiotensin IIAminobutyratesHeart Failure/CardiomyopathyMiddle AgedAngiotensin Receptor Antagonists/therapeutic useHospitalizationAngiotensin-Converting Enzyme Inhibitors/therapeutic useDrug CombinationsTreatment OutcomeTetrazoles/therapeutic useCardiologyValsartanFemaleCardiology and Cardiovascular Medicinemedicine.drugBenzimidazoles/therapeutic usemedicine.medical_specialtyAngiotensin II Type 1 Receptor Blockers/therapeutic usemedicine.drug_classPlaceboAngiotensin Receptor AntagonistsInternal medicineHumansEnalaprilFASTTrack Clinical ResearchBeta blockerAgedHospitalization/statistics & numerical dataHeart Failurebusiness.industryBiphenyl Compoundsmedicine.diseaseHeart Failure/drug therapyPlacebo EffectAngiotensin IICandesartanEndocrinologyAminobutyrates/therapeutic useHeart failureACE inhibitorBenzimidazolesbusinessAngiotensin II Type 1 Receptor BlockersSacubitril ValsartanNatriuretic peptide
researchProduct

Low- vs high-dose ARNI effects on clinical status, exercise performance and cardiac function in real-life HFrEF patients.

2022

Purpose Only a few studies are available on dose-related effects of sacubitril/valsartan (angiotensin receptor neprilysin inhibition (ARNI)) in real-life patients with heart failure and reduced ejection fraction (HFrEF). We sought to investigate clinical and functional effects in real-life HFrEF patients receiving ARNI at a different cumulative dose. Methods This was an observational study in consecutive outpatients admitted for HFrEF from October 2017 to June 2019. The PARADIGM criteria were needed for enrolment. ARNI was uptitrated according to blood pressure, drug tolerability, renal function and kaliemia. At least 10-month follow-up was required in each patient. Clinical assessment, Kan…

Malemedicine.medical_specialtyARNIBlood PressureWalk TestComorbiditySacubitrilVentricular Function LeftAngiotensin Receptor AntagonistsInternal medicinemedicine6-min walking test Aged Aminobutyrates Angiotensin Receptor Antagonists ARNI Biphenyl Compounds Blood Pressure Comorbidity Dose-Response Relationship Drug Drug Combinations Echocardiography Female Heart failure Humans Left ventricular function Male Middle Aged Prospective Studies Sacubitril/valsartan Stroke Volume Valsartan Ventricular Function Left Walk TestHumansPharmacology (medical)Sacubitril/valsartanProspective Studies6-min walking testAgedPharmacologyHeart FailureEjection fractionDose-Response Relationship DrugCumulative dosebusiness.industryAminobutyratesLeft ventricular functionBiphenyl CompoundsStroke VolumeGeneral MedicineMiddle Agedmedicine.diseaseClinical TrialARNI heart failure left ventricular function 6-minutes walking test Sacubitril/valsartan.Drug CombinationsBlood pressureTolerabilityValsartanEchocardiographyHeart failureCardiologyValsartanFemalebusinessSacubitril Valsartanmedicine.drugEuropean journal of clinical pharmacology
researchProduct

AT1-receptor blockade with irbesartan improves peripheral but not coronary endothelial dysfunction in patients with stable coronary artery disease

2007

Activation of the renin-angiotensin-aldosterone system plays an important role in the pathogenesis of endothelial dysfunction and atherosclerosis. Studies evaluating the effect of AT1-receptor blockers on endothelial dysfunction in patients with coronary artery disease (CAD) revealed mixed results. Studies addressing the effects of AT1-receptor blockers on the coronary and peripheral function in the same study population, are still lacking. We therefore aimed to test the effects of long-term therapy with the AT1-receptor blocker irbesartan (IRB) on both, the coronary and peripheral endothelial function in patients with CAD. Seventy-two patients with CAD were randomly assigned to double-blin…

Malemedicine.medical_specialtyBrachial ArteryEndotheliumTetrazolesCoronary Artery DiseaseCoronary artery diseaseIrbesartanDouble-Blind MethodInternal medicinemedicine.arterymedicineHumanscardiovascular diseasesEndothelial dysfunctionBrachial arteryUltrasonographybusiness.industryVascular diseaseBiphenyl CompoundsIrbesartanMiddle Agedmedicine.diseaseCoronary VesselsAngiotensin IIPeripheralVasodilationmedicine.anatomical_structureEndocrinologyRegional Blood FlowCardiologyFemaleEndothelium VascularCardiology and Cardiovascular MedicinebusinessAngiotensin II Type 1 Receptor Blockersmedicine.drugAtherosclerosis
researchProduct

Differential inhibition of biphenyl hydroxylation in perfused rat liver

1978

A differential inhibition of biphenyl hydroxylation by alpha-naphthoflavone and metyrapone was observed in isolated perfused rat liver. alpha-Naphthoflavone inhibited 2- and 4-hydroxylation in livers from beta-naphthoflavone-pretreated animals but had no effect on both reactions in livers from phenobarbital-pretreated animals. Metyrapone inhibited 2- and 4-hydroxylation in phenobarbital-stimulated livers, but only insignificant inhibition of 2-hydroxylation and a slight enhancement of 4-hydroxylation by metyrapone was observed in beta-naphthoflavone-stimulated livers. Conjugation of 2-hydroxybiphenyl and 4-hydroxybiphenyl by isolated perfused livers was also studied. 4-Hydroxybiphenyl prefe…

Malemedicine.medical_specialtyTime FactorsPharmacology toxicologyHydroxylationDifferential inhibitionHydroxylationchemistry.chemical_compoundCytochrome P-450 Enzyme SystemBiphenyl metabolismInternal medicinemedicineAnimalsFlavonoidsPharmacologyBiphenylMetyraponeBiphenyl CompoundsGeneral MedicineMetyraponeRatsEndocrinologyLiverchemistryDepression ChemicalPhenobarbitalRat livermedicine.drugNaunyn-Schmiedeberg's Archives of Pharmacology
researchProduct